Oncor sells business division to Ventana
This article was originally published in Clinica
Executive Summary
Oncor has sold assets relating to its in situ hybridisation business, including the Inform Her-2/Neu test for the detection of breast cancer, to Ventana Medical Systems for a total of up to $5.5 million. The company voluntarily surrendered assets relating to the business to secured creditors, who sold it to Ventana with Oncor's permission.